These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
317 related articles for article (PubMed ID: 36289334)
1. Neoadjuvant relatlimab and nivolumab in resectable melanoma. Amaria RN; Postow M; Burton EM; Tetzlaff MT; Ross MI; Torres-Cabala C; Glitza IC; Duan F; Milton DR; Busam K; Simpson L; McQuade JL; Wong MK; Gershenwald JE; Lee JE; Goepfert RP; Keung EZ; Fisher SB; Betof-Warner A; Shoushtari AN; Callahan M; Coit D; Bartlett EK; Bello D; Momtaz P; Nicholas C; Gu A; Zhang X; Korivi BR; Patnana M; Patel SP; Diab A; Lucci A; Prieto VG; Davies MA; Allison JP; Sharma P; Wargo JA; Ariyan C; Tawbi HA Nature; 2022 Nov; 611(7934):155-160. PubMed ID: 36289334 [TBL] [Abstract][Full Text] [Related]
2. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. Tawbi HA; Schadendorf D; Lipson EJ; Ascierto PA; Matamala L; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; De Menezes JJ; Dalle S; Arance A; Grob JJ; Srivastava S; Abaskharoun M; Hamilton M; Keidel S; Simonsen KL; Sobiesk AM; Li B; Hodi FS; Long GV; N Engl J Med; 2022 Jan; 386(1):24-34. PubMed ID: 34986285 [TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant Dual Checkpoint Inhibitors vs Anti-PD1 Therapy in High-Risk Resectable Melanoma: A Pooled Analysis. Mangla A; Lee C; Mirsky MM; Wang M; Rothermel LD; Hoehn R; Bordeaux JS; Carroll BT; Theuner J; Li S; Fu P; Kirkwood JM JAMA Oncol; 2024 May; 10(5):612-620. PubMed ID: 38546551 [TBL] [Abstract][Full Text] [Related]
4. Nivolumab/Relatlimab: A Novel Addition to Immune Checkpoint Inhibitor Therapy in Unresectable or Metastatic Melanoma. Phillips AL; Reeves DJ Ann Pharmacother; 2023 Jun; 57(6):738-745. PubMed ID: 36268952 [TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial. Rohaan MW; Stahlie EHA; Franke V; Zijlker LP; Wilgenhof S; van der Noort V; van Akkooi ACJ; Haanen JBAG BMC Cancer; 2022 Aug; 22(1):851. PubMed ID: 35927710 [TBL] [Abstract][Full Text] [Related]
6. Nivolumab/Relatlimab-rmbw: A Novel Dual Combination Therapy to Treat Adult and Pediatric Patients With Unresectable or Metastatic Melanoma. Thomas B; Burns M; Pervanas H; Ciurescu D; Dima L Am J Ther; 2023 Nov-Dec 01; 30(6):e526-e534. PubMed ID: 37921680 [TBL] [Abstract][Full Text] [Related]
7. Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma. Long GV; Stephen Hodi F; Lipson EJ; Schadendorf D; Ascierto PA; Matamala L; Salman P; Castillo Gutiérrez E; Rutkowski P; Gogas HJ; Lao CD; Janoski De Menezes J; Dalle S; Arance A; Grob JJ; Keidel S; Shaikh A; Sobiesk AM; Dolfi S; Tawbi HA NEJM Evid; 2023 Apr; 2(4):EVIDoa2200239. PubMed ID: 38320023 [TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial. Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421 [TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Blank CU; Rozeman EA; Fanchi LF; Sikorska K; van de Wiel B; Kvistborg P; Krijgsman O; van den Braber M; Philips D; Broeks A; van Thienen JV; Mallo HA; Adriaansz S; Ter Meulen S; Pronk LM; Grijpink-Ongering LG; Bruining A; Gittelman RM; Warren S; van Tinteren H; Peeper DS; Haanen JBAG; van Akkooi ACJ; Schumacher TN Nat Med; 2018 Nov; 24(11):1655-1661. PubMed ID: 30297911 [TBL] [Abstract][Full Text] [Related]
10. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Rozeman EA; Menzies AM; van Akkooi ACJ; Adhikari C; Bierman C; van de Wiel BA; Scolyer RA; Krijgsman O; Sikorska K; Eriksson H; Broeks A; van Thienen JV; Guminski AD; Acosta AT; Ter Meulen S; Koenen AM; Bosch LJW; Shannon K; Pronk LM; Gonzalez M; Ch'ng S; Grijpink-Ongering LG; Stretch J; Heijmink S; van Tinteren H; Haanen JBAG; Nieweg OE; Klop WMC; Zuur CL; Saw RPM; van Houdt WJ; Peeper DS; Spillane AJ; Hansson J; Schumacher TN; Long GV; Blank CU Lancet Oncol; 2019 Jul; 20(7):948-960. PubMed ID: 31160251 [TBL] [Abstract][Full Text] [Related]
12. Model-Informed Clinical Pharmacology Profile of a Novel Fixed-Dose Combination of Nivolumab and Relatlimab in Adult and Adolescent Patients with Solid Tumors. Zhao Y; Hu Z; Bathena SP; Keidel S; Miller-Moslin K; Statkevich P; Bello A; Roy A; Suryawanshi S Clin Cancer Res; 2024 Jul; 30(14):3050-3058. PubMed ID: 38295151 [TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant immunoradiotherapy results in high rate of complete pathological response and clinical to pathological downstaging in locally advanced head and neck squamous cell carcinoma. Leidner R; Crittenden M; Young K; Xiao H; Wu Y; Couey MA; Patel AA; Cheng AC; Watters AL; Bifulco C; Morris G; Rushforth L; Nemeth S; Urba WJ; Gough M; Bell RB J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33963014 [TBL] [Abstract][Full Text] [Related]
14. Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0-1 non-small cell lung cancer: the INCREASE trial. Dickhoff C; Senan S; Schneiders FL; Veltman J; Hashemi S; Daniels JMA; Fransen M; Heineman DJ; Radonic T; van de Ven PM; Bartelink IH; Meijboom LJ; Garcia-Vallejo JJ; Oprea-Lager DE; de Gruijl TD; Bahce I BMC Cancer; 2020 Aug; 20(1):764. PubMed ID: 32795284 [TBL] [Abstract][Full Text] [Related]
15. Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial. Ascierto PA; Lipson EJ; Dummer R; Larkin J; Long GV; Sanborn RE; Chiarion-Sileni V; Dréno B; Dalle S; Schadendorf D; Callahan MK; Nyakas M; Atkinson V; Gomez-Roca CA; Yamazaki N; Tawbi HA; Sarkis N; Warad D; Dolfi S; Mitra P; Suryawanshi S; Grob JJ J Clin Oncol; 2023 May; 41(15):2724-2735. PubMed ID: 36780608 [TBL] [Abstract][Full Text] [Related]
16. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Versluis JM; Menzies AM; Sikorska K; Rozeman EA; Saw RPM; van Houdt WJ; Eriksson H; Klop WMC; Ch'ng S; van Thienen JV; Mallo H; Gonzalez M; Torres Acosta A; Grijpink-Ongering LG; van der Wal A; Bruining A; van de Wiel BA; Scolyer RA; Haanen JBAG; Schumacher TN; van Akkooi ACJ; Long GV; Blank CU Ann Oncol; 2023 Apr; 34(4):420-430. PubMed ID: 36681299 [TBL] [Abstract][Full Text] [Related]